Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xinlikang granules for coronary heart disease with heart failure and reduced ejection fraction
ChiCTR2500098945Phase 2Recruiting
- Sponsor
- Nanyang Second General Hospital
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of enalapril in heart failure with reduced ejection fraction (HFrEF) and coronary arteriosclerosis (2 arms), sponsored by Nanyang Second General Hospital. Primary endpoints: Minnesota Heart Failure Quality of Life Questionnaire score, NYHA cardiac function class and 1 more. Started Mar 2025; status: recruiting.
02
Drugs
enalapril
03
Conditions
heart failure with reduced ejection fraction (HFrEF)coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2500098945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098945.